The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | Can venetoclax be used to treat multiple myeloma (MM)?
Philippe Moreau, MD, from the University Hospital of Nantes, Nantes, France, speaks about the potential of venetoclax in multiple myeloma (MM) treatment at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He discusses the current indications of this drug, and highlights that venetoclax is particularly effective in myeloma patients with the t(11,14) translocation. Prof. Moreau describes combination therapies including venetoclax, and speaks about the importance of further trials to determine the efficacy of venetoclax in different patient groups.
